• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amiko wins CE Mark to integrate drug sensor tech into inhalers

February 5, 2018 By Sarah Faulkner

AmikoAmiko Digital Health said today that it received CE Mark clearance to integrate its Respiro medication sensor tech with Teva Pharmaceuticals‘ (NYSE:TEVA) Spiromax inhaler, Chiesi‘s Nexthaler device and GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler.

The company’s Respiro platform is designed to help doctors monitor, in real-time, when and how well patients are using their medications.

“Respiro’s medication sensors capture data on true adherence behavior, which better reflects real-life patient inhaler use, as compared to traditional measures of adherence,” Job van Boven, assistant professor at the University Medical Center Groningen, said in prepared remarks. “This information can help us better understand the effectiveness of an inhaled drug therapy, and support the development of personalized and cost-effective interventions promoting adherence and correct inhaler technique.”

“Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology. By successfully completing this process, Amiko has demonstrated that Respiro complies with applicable EU’s health and safety legislative requirements and it can now offer the technology for clinical and commercial use to healthcare providers and research institutions in the EU,” Federica Iovine, Amiko’s director of regulatory affairs, added.

Having nabbed CE Mark clearance, Amiko plans to start commercializing Respiro in Europe later this year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: amiko, chiesigroup, GlaxoSmithKline plc, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS